In conclusion, the above indicated that in the low-risk group, when TGF-β was deficient, Th17 cells could convert to Th1 cells and release TNF-α, which in turn recruit neutrophils and ultimately have anti-cancer effects mechanistically. This evidence concerns the gene TGFB1 and cancer.